A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 900 shares of AVIR stock, worth $2,844. This represents 0.0% of its overall portfolio holdings.

Number of Shares
900
Previous 2,800 67.86%
Holding current value
$2,844
Previous $9,000 66.67%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.17 - $4.02 $220,777 - $279,976
69,646 Added 13.25%
595,249 $1.99 Million
Q2 2024

Aug 14, 2024

BUY
$3.31 - $4.04 $1.09 Million - $1.33 Million
329,603 Added 168.16%
525,603 $1.74 Million
Q1 2024

May 15, 2024

BUY
$3.09 - $4.56 $71,026 - $104,816
22,986 Added 13.29%
196,000 $791,000
Q4 2023

Feb 14, 2024

SELL
$2.8 - $3.35 $1.15 Million - $1.38 Million
-411,674 Reduced 70.41%
173,014 $527,000
Q3 2023

Nov 14, 2023

SELL
$3.0 - $3.79 $2.69 Million - $3.4 Million
-897,095 Reduced 60.54%
584,688 $1.75 Million
Q2 2023

Aug 14, 2023

SELL
$3.21 - $5.06 $320,759 - $505,620
-99,925 Reduced 6.32%
1,481,783 $5.54 Million
Q1 2023

May 15, 2023

BUY
$3.0 - $4.97 $2.93 Million - $4.85 Million
975,523 Added 160.93%
1,581,708 $5.3 Million
Q4 2022

Feb 14, 2023

BUY
$4.35 - $6.17 $1.36 Million - $1.93 Million
313,381 Added 107.03%
606,185 $2.92 Million
Q3 2022

Nov 14, 2022

BUY
$5.49 - $8.79 $185,287 - $296,662
33,750 Added 13.03%
292,804 $1.67 Million
Q2 2022

Aug 15, 2022

SELL
$5.33 - $8.18 $6.9 Million - $10.6 Million
-1,295,171 Reduced 83.33%
259,054 $1.84 Million
Q1 2022

May 16, 2022

SELL
$5.5 - $9.19 $630,888 - $1.05 Million
-114,707 Reduced 6.87%
1,554,225 $11.2 Million
Q4 2021

Feb 14, 2022

BUY
$7.67 - $44.59 $12 Million - $70 Million
1,569,450 Added 1577.62%
1,668,932 $14.9 Million
Q3 2021

Nov 15, 2021

BUY
$21.33 - $35.06 $895,881 - $1.47 Million
42,001 Added 73.07%
99,482 $3.49 Million
Q2 2021

Aug 16, 2021

BUY
$19.22 - $59.08 $1.03 Million - $3.16 Million
53,467 Added 1332.01%
57,481 $1.23 Million
Q1 2021

May 17, 2021

SELL
$41.42 - $88.44 $6.8 Million - $14.5 Million
-164,191 Reduced 97.61%
4,014 $248,000
Q4 2020

Feb 16, 2021

BUY
$26.36 - $41.78 $4.43 Million - $7.03 Million
168,205 New
168,205 $7.03 Million

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $263M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.